Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...
InvestorsHub on MSN
Recursion Pharmaceuticals rises 7% after reporting strong mid-stage data in FAP study
Recursion Pharmaceuticals (NASDAQ:RXRX) gained 7% on Monday after releasing encouraging Phase 2 results for REC-4881, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback